ArticleBMC medicine2025
Longitudinal patterns of antidepressant and benzodiazepine use associated with injurious falls in older adults with depression: a retrospective cohort study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of potentially inappropriate medication use and its association with hospitalization among older adults with chronic disease in the Amhara region, Ethiopia: a multicenter prospective cohort study.Therapeutic advances in drug safety · 2026Article
- From vital sign trajectories to data-driven targets: defining exploratory blood gas ranges in sepsis-associated thrombocytopenia.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCross-sectional studies have shown that antidepressants (ADs) and benzodiazepines (BZDs) are commonly co-prescribed for depression, potentially increasing the risk of falls and related injuries (FRI) compared to monotherapies. However, little is known about the longitudinal dosing patterns (i.e., trajectory) of ADs and BZDs and their associated FRI risk.
methodsThis retrospective cohort study used group-based multi-trajectory models to identify AD-BZD trajectories among older Medicare fee-for-service beneficiaries with depression initiating ADs with/without BZDs. We measured the standardized daily doses of AD and BZD within 84 days after AD initiation and categorized them into negligible, very-low, low, moderate, high, or very-high levels with a discontinuing, declining, increasing, or stable trend. Then, we assessed the subsequent 12-month FRI risk associated with each trajectory.
resultsAmong 102,750 eligible beneficiaries, the mean age was 75.5 years (SD = 7.5); 67.0% were female, 81.2% were White, and 4.9% experienced an FRI. We identified 12 distinct AD/BZD trajectories, of which 79,424 patients received AD monotherapy, and 23,326 patients received both ADs and BZDs. Compared with Group A (low discontinuing AD; 17.3% of the cohort; FRI crude incidence rate = 99.7/1000 person-year), trajectories with a higher dose or a longer duration of AD use were associated with an increased FRI risk, regardless of BZD use. The hazard ratios (HR) and 95% confidence intervals (CI) for Groups B (low declining AD; 31.0% of the cohort), C (moderate increasing AD; 23.5%), and D (high increasing AD; 5.4%) were 1.11 (1.04-1.19), 1.24 (1.16-1.32), and 1.29 (1.16-1.42), respectively. Combining ADs and BZDs at very-low doses or with declining trends did not significantly alter FRI risk compared to AD monotherapy. However, FRI risk increased when BZDs were used at low doses (either with stable or increasing trends). The HR and 95%CI for Groups J (moderate increasing AD/low stable BZD, 1.3%) and L (very-high increasing AD/low-dose increasing BZD) were 1.71 (1.41, 2.08) and 1.96 (1.53, 2.49), respectively.
conclusionsWe observed a dose-response relationship between AD use and FRI risk, independent of BZD use, highlighting the importance of initiating ADs at the lowest effective dose and closely monitoring to prevent FRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.